Lytix Biopharma AS (DE:6BG) has released an update.
Lytix Biopharma AS has reported significant clinical advancements in Q1 2024, with two Phase II studies on their leading cancer drug candidate showing positive results for skin cancer treatments. Additionally, they’ve secured strong shareholder support through a successful NOK 50 million fundraising effort. The company anticipates further study updates in the second half of 2024 and is preparing to initiate a new study for early-stage melanoma patients.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.
